SKOKIE, Ill.--(BUSINESS WIRE)--May 3, 2019--
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced a poster presentation at the 2019 American Academy
of Neurology (AAN) Annual Meeting in Philadelphia, Pa. The poster is
titled “Spherical Nucleic Acids Show Increased Distribution and Longer
Persistence than Linear Oligonucleotides in Rat Brain Following IT
Administration” and will be presented by Weston Daniel, Senior Director
of Program Management at Exicure.
Session Date/Times: Sunday, May 5, 2019 from 11:30 a.m. to 6:30 p.m. ET
Presentation number: 6-032
Poster session 1: Child Neurology: Neurogenetics poster grouping within
Poster Neighborhood Number 6
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing
therapeutics for immuno-oncology, inflammatory diseases and genetic
disorders based on our proprietary Spherical Nucleic Acid, or SNA
technology. We believe Exicure's proprietary SNA architecture has
distinct chemical and biological properties that may provide advantages
over other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients
with advanced solid tumors. Exicure is based outside of Chicago, IL.www.exicuretx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005026/en/
Source: Exicure, Inc.
MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com